Eloxx Pharmaceuticals Board Changes
Ticker: ELOX · Form: 8-K · Filed: Oct 17, 2024 · CIK: 1035354
| Field | Detail |
|---|---|
| Company | Eloxx Pharmaceuticals, Inc. (ELOX) |
| Form Type | 8-K |
| Filed Date | Oct 17, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.01, $0 |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, management
TL;DR
Eloxx Pharma board shakeup: Dr. Jonathan Drachman joins, David Johnson exits.
AI Summary
Eloxx Pharmaceuticals, Inc. announced on October 16, 2024, a change in its board of directors. Specifically, Dr. Jonathan G. Drachman has been appointed as a new director, and Mr. David E. Johnson has resigned from the board. The company also disclosed compensatory arrangements for certain officers.
Why It Matters
Changes in board composition can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes can introduce uncertainty about future strategic direction and leadership stability.
Key Players & Entities
- Eloxx Pharmaceuticals, Inc. (company) — Registrant
- Dr. Jonathan G. Drachman (person) — Newly appointed director
- Mr. David E. Johnson (person) — Resigned director
- October 16, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as a new director to the Eloxx Pharmaceuticals board?
Dr. Jonathan G. Drachman has been appointed as a new director.
Who has resigned from the Eloxx Pharmaceuticals board?
Mr. David E. Johnson has resigned from the board.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is October 16, 2024.
What is the state of incorporation for Eloxx Pharmaceuticals, Inc.?
Eloxx Pharmaceuticals, Inc. is incorporated in Delaware.
What other information is disclosed regarding company officers in this filing?
The filing also discloses compensatory arrangements of certain officers.
Filing Stats: 668 words · 3 min read · ~2 pages · Grade level 11.9 · Accepted 2024-10-17 16:01:29
Key Financial Figures
- $0.01 — e on which registered Common Stock, $0.01 par value per share ELOX OTC Pink Mar
- $0 — mended to reduce such exercise price to $0.0001, the closing price per share of th
Filing Documents
- tm2426349d1_8k.htm (8-K) — 30KB
- tm2426349d1_ex10-1.htm (EX-10.1) — 68KB
- 0001104659-24-109521.txt ( ) — 282KB
- elox-20241016.xsd (EX-101.SCH) — 3KB
- elox-20241016_lab.xml (EX-101.LAB) — 33KB
- elox-20241016_pre.xml (EX-101.PRE) — 22KB
- tm2426349d1_8k_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1* Form of Amendment to Stock Option Agreement, dated October 16, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 17, 2024 ELOXX PHARMACEUTICALS, INC. By: /s/ Sumit Aggarwal Name: Sumit Aggarwal Title: President and Chief Executive Officer